Manager, Cost Accounting
Cogent Biosciences Inc - Waltham, Massachusetts, United States
Posted Oct 5, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Not verified
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Offered From the posting source checked Nov 16, 2026
- Verification
- Not verified checked Nov 20, 2026
- Salary
- $135K-$155K From the posting source checked Nov 16, 2026
- 401(k) match
- Reported from DOL Form 5500 industry filing (not employer-specific)
Was this benefit information wrong? Tell us.
Market context
- U.S. role benchmark (BLS OEWS)
- $106,409 U.S. median for this role
- Projected growth (BLS Employment Projections)
- +7.7% - Faster than average
36% above the BLS role benchmark for finance aggregate.
Matched to SOC 13-2011 - Finance aggregate by role bucket.
Source:U.S. Bureau of Labor Statistics, OEWS, May 2024andEmployment Projections, 2024-2034.
Role
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Company
- Equity
- Offered Verified - SEC 10-K source checked Nov 16, 2026
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Manager, Cost Accounting Waltham, Massachusetts, United States Who We Are: Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has exhibited promising initial data across all three trials: APEX in AdvSM, SUMMIT in NonAdvSM and PEAK in GIST, including an encouraging safety profile across 600+ patients in single agent and combination dosing. The Role: Cogent Biosciences is preparing for its first commercial launch and we are seeking a Manager, Cost Accounting to build and maintain the inventory and cost of goods sold processes. This role is responsible for ensuring accurate product costing, inventory valuation, variance analysis, and financial reporting in compliance with U.S. GAAP. This is a hands-on builder role suited for an experienced accountant with an expertise in pharmaceutical industry accounting practices, standard costing methodologies, inventory controls, and designing scalable accounting processes. This position reports to the Commercial Accounting Leader and will partner closely with Supply Chain, FP&A, Quality, Technical Operations, external vendors, and senior finance leadership to support the Company's transition to a commercial-stage organization. Responsibilities: - Maintain
Read the full description at job-boards.greenhouse.io. FewerJobs shows a preview and links to the original posting.
Apply link verified; last checked Nov 20, 2026.
What verified means
Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.
Related jobs
Associate Director, Accounting Operations
Cogent Biosciences Inc - Waltham, Massachusetts, United States
Cost Accounting Manager
Ansa Biotechnologies - Emeryville, CA
Director, Revenue and Cost Accounting
Corcept Therapeutics - Redwood City, California, United States
Manager- Cost Accounting
Cryoport Inc - Irvine, California